The trust's revenue trajectory has contracted sharply by 81.13% year-over-year, while a rigid cost structure maintains an 87.75% operating margin that fails to scale with declining investment income.
| Metric | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Sales/Revenue | 40.69M | 215.58M | -1.65B | -639.7M |
| Revenue Growth % | -81.13% | 113.04% | -158.48% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 40.69M | 215.58M | -1.65B | -639.7M |
| Gross Margin % | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | -81.13% | 113.04% | -158.48% | - |
| Operating Expenses | 4.99M | 4.01M | 2.8M | 948.69K |
| OpEx % of Revenue | 12.25% | 1.86% | -0.17% | -0.15% |
| Selling, General & Admin | 4.41M | 3.8M | 2.61M | 1.18M |
| SG&A % of Revenue | 10.84% | 1.76% | -0.16% | -0.18% |
| Research & Development | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 576K | 209.79K | 194.86K | -233.83K |
| Operating Income | 35.7M | 211.57M | -1.66B | -640.65M |
| Operating Margin % | 87.75% | 98.14% | 100.17% | 100.15% |
| Operating Income Growth % | -83.12% | 112.77% | -158.54% | - |
| EBITDA | 35.7M | 211.57M | -1.66B | -640.65M |
| EBITDA Margin % | 87.75% | 98.14% | 100.17% | 100.15% |
| EBITDA Growth % | -83.12% | 112.77% | -158.54% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 |
| EBIT | -35.72M | -211.57M | 0 | 0 |
| Net Interest Income | -15.44K | -1.5K | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 15.44K | 1.5K | 0 | 0 |
| Other Income/Expense | 0 | 0 | 0 | 0 |
| Pretax Income | 35.7M | 211.57M | -1.66B | -640.65M |
| Pretax Margin % | 87.75% | 98.14% | 100.17% | 100.15% |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | 35.7M | 211.57M | -1.66B | -640.65M |
| Net Margin % | 87.75% | 98.14% | 100.17% | 100.15% |
| Net Income Growth % | -83.12% | 112.77% | -158.54% | - |
| Net Income (Continuing) | 35.7M | 211.57M | -1.66B | -640.65M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.17 | 0.98 | -6.91 | -2.58 |
| EPS Growth % | -82.65% | 114.18% | -167.83% | - |
| EPS (Basic) | 0.17 | 0.98 | -6.91 | -2.58 |
| Diluted Shares Outstanding | 215.89M | 215.89M | 239.7M | 248.31M |
| Basic Shares Outstanding | 215.89M | 215.89M | 239.7M | 248.31M |
| Dividend Payout Ratio | 517.37% | 83.24% | - | - |
NAV discount and liquidity
As reported in recent financial disclosures, BTX experienced a sharp 81.13% year-over-year decline in revenue, reflecting a significant cooling in the IPO market and a reduced capacity for the trust to realize capital gains from its growth-oriented biotechnology and technology holdings during the current period.
The dramatic contraction in top-line figures suggests that the trust's exit strategy for its private and mid-cap holdings has faced substantial headwinds. Investors should monitor whether this decline represents a temporary pause in liquidity events or a more structural impairment of the underlying portfolio's valuation.
Based on the trust's reported figures, the high 87.75% operating margin masks a rigid cost structure where advisory fees paid to BlackRock remain relatively static, creating potential downward pressure on net asset value as investment income fails to scale proportionally with the trust's administrative and management overhead.
The persistence of high operating margins despite a collapse in revenue indicates that the trust's expense base is largely decoupled from its investment performance. This lack of operational flexibility may warrant further investigation into how management intends to preserve capital if the current environment of suppressed realized gains continues.
According to institutional analysis of the trust's structure, there is a risk that reported distributions may rely on Return of Capital rather than genuine investment earnings, which appears to be a common concern given the significant volatility in realized gains and the trust's current income generation profile.
Investors should distinguish between total return on NAV and headline income figures to assess the true economic health of the trust. Relying on capital distributions during periods of NAV decline may be value-destroying and suggests that the quality of earnings is currently compromised by the lack of exit opportunities.
As indicated by the persistent discount to NAV, the market appears to be pricing in significant skepticism regarding the carrying value of the trust's Level 3 private assets, which are marked-to-model and may not fully reflect the current interest rate-driven valuation compression in the biotechnology sector.
The discrepancy between the trust's internal valuations and market pricing suggests that investors are discounting the liquidity premium of the private holdings. This warrants caution, as any future mark-downs of these illiquid assets could lead to further erosion of the trust's net asset value.
Quick answers to the most common questions about buying BTX stock.
For fiscal year 2024, BlackRock Technology and Private Equity Term Trust (BTX) reported total revenue of $40.7M.
BlackRock Technology and Private Equity Term Trust (BTX) is profitable, generating $35.7M in net income for the fiscal year ending 2024 with a net profit margin of 87.7%.
BlackRock Technology and Private Equity Term Trust (BTX) reported an operating income of $35.7M, resulting in an operating profit margin of 87.7%. This margin reflects the operational efficiency of the business before interest and taxes.
BlackRock Technology and Private Equity Term Trust (BTX) generated $40.7M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.